We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Partnership with Lilly Expands Qiagen’s Personalized Healthcare Pipeline

By LabMedica International staff writers
Posted on 03 Jun 2014
Qiagen (Hilden, Germany) and Eli Lilly (Indianapolis, Indiana, USA) will codevelop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. More...
The agreement includes the development of tests that will be based on Qiagen’s multimodal, multianalyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test. The development of modular assay panels focuses on multiple biomarkers targeting cellular pathways associated with cancer therapies under development by Lilly.

Qiagen offers companion diagnostic programs spanning a range of molecular testing platforms, including real-time polymerase chain reaction (PCR) assays for use on Qiagen’s QIAsymphony family and next-generation sequencing (NGS) panels. QIAGEN also offers a novel, multimodal, multianalyte platform from PrimeraDx. The proprietary technology enables laboratories to process multiple samples in a fast, cost-efficient run. The technology allows the analysis of dozens of DNA and RNA biomarkers as well as their copy numbers, expression levels and mutations in one assay and at the same time.

The Modaplex platform was cleared by the US Food and Drug Administration (FDA; Silver Spring, MD, USA) in December 2013.

“We believe our technology can enhance Lilly’s development of innovative therapies for the benefit of cancer patients. In addition to a broad portfolio of PCR-based assays targeting more than 25 biomarkers, Qiagen’s Personalized Healthcare offering has expanded to include universal solutions using next-generation sequencing (NGS) and now also a unique and proprietary multimodal, multianalyte testing technology. Our collaborations with Lilly are among more than 20 co-development and co-commercialization projects underway with leading pharmaceutical and biotechnology companies.”

Richard B. Gaynor, MD, Senior VP, Oncology-Clinical Product Development and Medical Affairs, of Lilly, said: “Certain applications in biomarker development for tailoring oncology therapeutics require the combined analysis of DNA and RNA, and this collaboration provides a multimodal, multianalyte solution that can process multiple sample types and biomarkers in a single test.”

Related Links:

Qiagen
Eli Lilly
FDA



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automatic CLIA Analyzer
Shine i6000
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.